Translational breast cancer research : a journal focusing on translational research in breast cancer最新文献

{"title":"OneMark™ breast localisation: integrating diagnosis and surgical guidance-a narrative review.","authors":"Janhavi Venkataraman, Anmol Malhotra, Kefah Mokbel","doi":"10.21037/tbcr-2026-1-0009","DOIUrl":"10.21037/tbcr-2026-1-0009","url":null,"abstract":"<p><strong>Background and objective: </strong>Wire-free breast localisation technologies have largely replaced wire-guided localisation and improved patient comfort and scheduling flexibility. However, most currently available systems retain a fundamental inefficiency: diagnostic biopsy and definitive surgical localisation remain separate procedural events. OneMark™ breast localisation proposes an alternative paradigm by integrating diagnostic marking and intraoperative localisation into a single step at the time of biopsy. This article evaluates whether such pathway efficiency represents a meaningful clinical advance or an unproven conceptual ambition.</p><p><strong>Methods: </strong>This narrative review and critical appraisal examine the conceptual basis, proposed clinical applications, and pathway implications of the OneMark™ breast localisation system. Evidence was derived from publicly accessible U.S. Food and Drug Administration (FDA) clearance documentation, manufacturer-provided technical information, clinical trial registry data, and hands-on device evaluation by the senior authors using <i>ex vivo</i> breast tissue and a recently published cadaver-based simulation study assessing detection time and visibility. This informal <i>ex vivo</i> assessment was undertaken to familiarise the investigators with the technology and was not intended as a formal performance evaluation. No published peer-reviewed clinical outcome data are currently available.</p><p><strong>Key content and findings: </strong>OneMark™ employs a hydrogel marker containing Doppler-visible microparticles and a metallic clip, deployed at diagnostic biopsy and subsequently localised intraoperatively using surgeon-operated Doppler-based detection with visual and auditory feedback. The primary proposed advantage is pathway efficiency, eliminating the need for a separate pre-operative localisation procedure. Additional theoretical benefits include potential deployability across imaging-guided biopsy settings, including neoadjuvant systemic therapy, minimal magnetic resonance imaging (MRI) artefact, small marker size facilitating nodal deployment, and potential applicability in bracketing multifocal and extensive disease. Preliminary information suggests a lower cost compared with established wire-free localisation technologies. Preclinical cadaver-based simulation has demonstrated detection times comparable to standard biopsy clips and significantly superior visibility ratings, particularly for posterior lesions, with surgeons valuing audible Doppler feedback. However, clinical performance, reliability across anatomical sites, and oncological outcomes remain unvalidated.</p><p><strong>Conclusions: </strong>OneMark™ represents a pathway-focused innovation that challenges the conventional two-step localisation model rather than offering incremental technical refinement. While the conceptual rationale is compelling, its clinical value remains contingent on prospective clinical va","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"34"},"PeriodicalIF":1.4,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer as an evolutionary reversal-time for a paradigm shift.","authors":"Rainer J Klement","doi":"10.21037/tbcr-2026-1-0012","DOIUrl":"10.21037/tbcr-2026-1-0012","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"38"},"PeriodicalIF":1.4,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative outcomes of conventional versus endoscopic-assisted surgery for breast phyllodes tumors: a single center retrospective cohort study.","authors":"Zilin Zhuang, Di Huang, Linbin Yang, Jiannan Wu, Liang Jin, Xun Li, Zhiyun Qian, Rong Lei, Xiaojun Li, Erwei Song, Yan Nie","doi":"10.21037/tbcr-2026-1-0005","DOIUrl":"10.21037/tbcr-2026-1-0005","url":null,"abstract":"<p><strong>Background: </strong>Breast phyllodes tumors (PTs) tend to grow rapidly and often present as large tumors. Consequently, conventional surgery (CS) typically leaves large and conspicuous scars on the breast. In contrast, endoscopic-assisted surgery (EAS) via the axillary approach offers smaller, more concealed incisions, leaving the breast surface unscarred. However, whether this technique can enhance aesthetic outcomes without increasing the risk of PTs recurrence remains unclear. The study aimed to compare the oncologic safety and cosmetic outcomes of EAS versus CS in patients with PTs.</p><p><strong>Methods: </strong>Patients with newly diagnosed PTs who received surgical treatment were included, and they were stratified into two groups: EAS group and CS group. Propensity score matching (PSM) was used to balance the baseline differences between two groups. Oncologic safety, cosmetic satisfaction, intraoperative indicators, and postoperative complications were compared between patients underwent EAS and CS.</p><p><strong>Results: </strong>After 3:1 PSM, 200 patients were included in the final analysis (147 CS and 53 EAS). The median follow-up was 23.77 months. EAS was associated with a significantly longer operative time (83.77±26.81 <i>vs</i>. 73.44±34.66 min, P=0.01) but yielded superior cosmetic outcomes, as evidenced by higher BREAST-Q scores for breast satisfaction (76.81±9.15 <i>vs</i>. 69.21±9.64, P<0.001) and psychological well-being (91.16±6.69 <i>vs</i>. 85.17±11.71, P<0.001). Postoperative complications and intraoperative blood loss did not differ significantly. Oncologic outcomes were comparable between the groups, with similar 3-year local recurrence-free survival (LRFS; 97.0% EAS <i>vs</i>. 93.4% CS), distant metastasis-free survival (DMFS; 100% EAS <i>vs</i>. 97.5% CS), and overall survival (OS; 100% EAS <i>vs</i>. 98.3% CS).</p><p><strong>Conclusions: </strong>In this matched cohort study, EAS approved to be a safe and feasible substitute to CS for PTs, offering equivalent oncologic outcomes while significantly improving cosmetic satisfaction and psychological well-being.</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"23"},"PeriodicalIF":1.4,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted axillary dissection versus sentinel lymph node biopsy after neoadjuvant chemotherapy: are we underestimating the clinical significance of staging accuracy?","authors":"Janhavi Venkataraman, Kefah Mokbel","doi":"10.21037/tbcr-2026-1-0006","DOIUrl":"10.21037/tbcr-2026-1-0006","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"37"},"PeriodicalIF":1.4,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence and gaps in tumor-agnostic therapies for breast cancer: a narrative review.","authors":"Daniel Thomas Jones, Rishi Kumar Nanda, Manraj Dhillon, Aishwarya Hanspal, Erij Nile Makhdoom, Jason Ta, Ramaditya Srinivasmurthy, Abbas Ali Hussain, Riccesha Hattin, Tommy Vu, Yin Mon Myat, Hazem Aboaid, Kyaw Zin Thein","doi":"10.21037/tbcr-2025-1-69","DOIUrl":"10.21037/tbcr-2025-1-69","url":null,"abstract":"<p><strong>Background and objective: </strong>Tumor-agnostic therapies enable treatment selection based on shared molecular alterations rather than tissue of origin and represent a central advancement in precision oncology. Since 2017, multiple U.S. Food and Drug Administration (FDA) approvals have validated this biomarker-driven framework across solid tumors. Clinical applicability in breast cancer is limited by the low prevalence of actionable tumor-agnostic biomarkers and minimal representation of breast tumors in pivotal registrational trials. This review evaluates the biological rationale, clinical evidence, and relevance of tumor-agnostic therapies in breast cancer.</p><p><strong>Methods: </strong>A structured literature search was conducted using PubMed/MEDLINE, Embase, ClinicalTrials.gov, and FDA regulatory documents from database inception through November 2025. Search terms included tumor-agnostic, tissue-agnostic, basket trials, and biomarker-specific therapies. Inclusion was restricted to FDA-approved tumor-agnostic therapies supported by prospective clinical or registration-enabling data.</p><p><strong>Key content and findings: </strong>Nine FDA-approved tumor-agnostic therapies across multiple mechanistic classes were identified. Breast cancer representation in pivotal datasets was limited or absent in most approvals. Several therapies were supported by datasets that included no breast cancer patients, while others included only one to three cases. The largest breast cancer subgroups included fewer than fifteen patients. Clinical activity was observed in select contexts, particularly NTRK fusion-positive tumors and hypermutated cancers treated with immune checkpoint inhibitors. Most available evidence in breast cancer is derived from extrapolation across non-breast tumor types.</p><p><strong>Conclusions: </strong>Tumor-agnostic therapies represent a biologically valid treatment strategy for rare molecular subsets of breast cancer. Clinical implementation is constrained by low biomarker prevalence, limited disease-specific evidence, and absence of robust survival data. A selective, guideline-informed approach using comprehensive genomic profiling in metastatic disease is appropriate. Expansion of breast-specific evidence through histology-enriched trials, prospective registries, and standardized molecular diagnostics is required to define the role of tumor-agnostic therapies in breast oncology.</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"30"},"PeriodicalIF":1.4,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of different non-surgical scar reduction methods in post-operative scars: a systematic review and meta-analysis.","authors":"Genevieve Chin Xuen Heng, Zhao Qi Charles Wang, Rachel Xue Ning Lee, Clement Luck Khng Chia","doi":"10.21037/tbcr-25-59","DOIUrl":"10.21037/tbcr-25-59","url":null,"abstract":"<p><strong>Background: </strong>Effective scar management is crucial in improving cosmetic outcomes, restoring physiological function, and supporting psychological well-being in surgical patients. This systematic review and meta-analysis aims to evaluate the effectiveness of post-operative scar reduction techniques in optimising wound healing and minimising scar formation.</p><p><strong>Methods: </strong>PubMed (Medline), National University of Singapore (NUS) Library, ResearchGate and Springerlink were searched by two independent researchers up to 30th October 2024. Eligible studies compared Vancouver Scar Scale (VSS), Visual Analogue Scale (VAS) and Patient Observer Scar Assessment Scale (POSAS) scores across different studies and their respective scar reduction techniques on post-operative patients. English-language human studies on post-surgical management with scar-related outcomes were included while non-English, non-human, non-surgical, duplicate studies and scars covering burns were excluded. Risk of bias was assessed using the Cochrane risk-of-bias assessment tool. A quantitative synthesis of the results was performed using available outcome data and effect sizes were plotted using forest plots.</p><p><strong>Results: </strong>A total of 20 studies (1995-2024) including 1,089 post-surgical patients were appraised. Each scar reduction technique was found to have produced significant improvements in different aspects of scar reduction. Fractional CO2 laser produced stable and significant improvements in pliability and texture. Meanwhile, botulinum toxin A (BTX-A) showed moderate-to-strong efficacy, particularly in high-tension areas like the face and chest. Silicone gel demonstrated improvement in pigmentation and pliability in hypertrophic scars, and pulsed dye laser (PDL) was known to significantly reduce scar height and vascularity.</p><p><strong>Conclusions: </strong>This demonstrates that all four non-invasive interventions-silicone gel, PDL, fractional CO2 laser, and BTX-A-are associated with measurable improvements in scar reduction and appearance. Early intervention and employing a multimodal approach may result in an overall enhanced outcome across multiple dimensions of scar reduction.</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"26"},"PeriodicalIF":1.4,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MRI-guided de-escalation in HER2-positive early breast cancer: precision progress with necessary prudence.","authors":"Aydah AlAwadhi, Kefah Mokbel","doi":"10.21037/tbcr-2026-1-0015","DOIUrl":"10.21037/tbcr-2026-1-0015","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"39"},"PeriodicalIF":1.4,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: The preliminary study on the effect of PSEN1 on the proliferation and invasion of breast cancer cells.","authors":"","doi":"10.21037/tbcr-2026-0046","DOIUrl":"10.21037/tbcr-2026-0046","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.21037/tbcr-25-42.].</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"40"},"PeriodicalIF":1.4,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current perspectives on circulating tumor DNA in breast cancer: a narrative review.","authors":"Chikako Funasaka, Yoichi Naito","doi":"10.21037/tbcr-25-23","DOIUrl":"10.21037/tbcr-25-23","url":null,"abstract":"<p><strong>Background and objective: </strong>In recent years, research and development of cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) as cancer biomarkers for use in diagnosis, prognosis, and monitoring of therapeutic responses have progressed. ctDNA has become an important focus for biomarker analysis in breast cancer and in current clinical trials. This review aims to discuss the current status and future prospects of ctDNA in breast cancer.</p><p><strong>Methods: </strong>We provide a Narrative Review about ctDNA in breast cancer. We used PubMed to search for reports of ctDNA in breast cancer. We also searched the clinicaltrials.gov database and the Cochrane Library for clinical trials involving ctDNA analysis in breast cancer and other cancer types up to November 30, 2025 (reviewed November 30, 2025). We reviewed all articles written in English, including clinical trials, meta-analyses, and prospective and retrospective studies.</p><p><strong>Key content and findings: </strong>The uses of ctDNA in breast cancer can currently be broadly classified into the following categories: (I) cancer screening; (II) prediction of treatment response in the neoadjuvant setting; (III) monitoring of minimal residual disease; (IV) assessment of the genomic landscape for treatment selection; and (V) monitoring clonal evolution. Clinical trials are underway to assess ctDNA-guided therapy and interventions for ctDNA-positive cases with poor prognosis, especially in the perioperative period. ctDNA is present at low concentrations in the blood in early-stage breast cancer, and a highly sensitive method is needed to detect ctDNA. The U.S. Food and Drug Administration has developed draft guidance regarding the use of ctDNA in therapeutic development.</p><p><strong>Conclusions: </strong>ctDNA has become important as a source of biomarkers in clinical trials, and its clinical and research significance is expected to increase.</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"31"},"PeriodicalIF":1.4,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complications, patient satisfaction, clinical outcomes, and aesthetic outcomes of nipple-sparing <i>vs</i>. skin-sparing mastectomies: a systematic review and meta-analysis.","authors":"Saad Badat, Mustafa M Houmsse, Ahmed Adham R Elsayed, Marc D Basson","doi":"10.21037/tbcr-2025-1-86","DOIUrl":"10.21037/tbcr-2025-1-86","url":null,"abstract":"<p><strong>Background: </strong>Nipple-sparing mastectomy (NSM) and skin-sparing mastectomy (SSM) are widely used conservative mastectomy techniques that preserve native breast skin, with NSM additionally maintaining the nipple-areola complex (NAC). This systematic review and meta-analysis aims to compare postoperative complications, patient satisfaction, and clinical and aesthetic outcomes between NSM and SSM in breast cancer patients.</p><p><strong>Methods: </strong>We performed a systematic review in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searching PubMed, Cochrane Library, Web of Science, and the Virtual Health Library (September 9, 2025) for original studies directly comparing NSM and SSM in women with breast cancer. Two reviewers independently screened records, extracted data, and assessed quality using STROBE and CARE checklists and the ROBINS-I tool. Crude pooled incidences were calculated for postoperative complications, and quantitative analyses were conducted using odds ratios with 95% confidence intervals where at least two comparative studies reported a given outcome.</p><p><strong>Results: </strong>Twenty-one studies, including 7,032 patients (1,195 NSM; 1,671 SSM), met inclusion criteria. NSM was associated with higher odds of skin-flap necrosis than SSM (odds ratio 2.20; 95% confidence interval: 1.07-4.55), whereas rates of surgical-site infection, hematoma, seroma, venous thromboembolism, and wound dehiscence were low and generally similar between techniques. Despite more ischemic complications, NSM did not show higher rates of implant or tissue-expander loss, reconstruction failure, or radiation-associated complications. Across most studies, NSM yielded superior aesthetic outcomes, better preservation of nipple sensation, and higher scores for psychosocial well-being, breast satisfaction, and reduced postoperative regret, although SSM sometimes achieved more favorable aesthetic ratings after postmastectomy radiotherapy.</p><p><strong>Conclusions: </strong>Compared with SSM, NSM offers advantages in patient-reported and sensory outcomes at the cost of an increased odds of skin-flap necrosis and delayed wound healing, without clear differences in other major complications or oncologic safety. NSM appears best suited for carefully selected, nonsmoking patients with low body mass index and minimal breast ptosis, while SSM remains an important option for patients with larger or ptotic breasts, NAC involvement, or anticipated radiotherapy. Procedure selection should be individualized based on anatomy, oncologic factors, and patient priorities. This review may be limited by the heterogeneity and retrospective nature of the included studies. Additionally, the descriptive nature of pooled incidences and the potential for manual data extraction errors should be considered when interpreting the results.</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"7 ","pages":"24"},"PeriodicalIF":1.4,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}